Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 6 (2009), Issue 5 (May)

1. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents.
   BMC Musculoskelet Disord, 10: 41. [Abstract] [Full-text]
2. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
   Ann Rheum Dis, 68(6): 789-96. [Abstract] [Full-text]
3. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.
   Ann Rheum Dis, 68(6): 797-804. [Abstract] [Full-text]
4. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
   Ann Rheum Dis, 68(6): 805-11. [Abstract] [Full-text]
5. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis.
   Ann Rheum Dis, 68(6): 972-5. [Abstract] [Full-text]
6. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group.
   Ann Rheum Dis, 68(6): 930-7. [Abstract] [Full-text]
7. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
   Ann Rheum Dis, 68(6): 914-21. [Abstract] [Full-text]
8. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
   Ann Rheum Dis, 68(6): 1011-6. [Abstract] [Full-text]
9. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
   Ann Rheum Dis, 68(6): 868-72. [Abstract] [Full-text]
10. Dissecting the contribution of innate and antigen-specific pathways to the breach of self-tolerance observed in a murine model of arthritis.
    Ann Rheum Dis, 68(6): 1059-66. [Abstract] [Full-text]
11. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
    Ann Rheum Dis, 68(6): 1044-50. [Abstract] [Full-text]
12. Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis.
    Ann Rheum Dis, 68(6): 898-903. [Abstract] [Full-text]
13. Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis.
    Ann Rheum Dis, 68(6): 1036-43. [Abstract] [Full-text]
14. Thymic function in juvenile idiopathic arthritis.
    Ann Rheum Dis, 68(6): 983-90. [Abstract] [Full-text]
15. Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis.
    Ann Rheum Dis, 68(6): 879-84. [Abstract] [Full-text]
16. Severe alterations in expression and localisation of {alpha}6{beta}4 integrin in salivary gland acini from patients with Sjogren syndrome.
    Ann Rheum Dis, 68(6): 991-6. [Abstract] [Full-text]
17. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Ann Rheum Dis, 68(6): 844-9. [Abstract] [Full-text]
18. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
    Ann Rheum Dis, 68(6): 823-7. [Abstract] [Full-text]
19. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Ann Rheum Dis, 68(6): 954-60. [Abstract] [Full-text]
20. An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis.
    J Pharmacol Exp Ther, 329(3): 1100-9. [Abstract] [Full-text]
21. Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis.
    Med Hypotheses, 73(2): 201-2. [Abstract] [Full-text]
22. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
    Clin Rheumatol, 28(7): 787-91. [Abstract] [Full-text]
23. Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis.
    Clin Rheumatol, 28(7): 767-75. [Abstract] [Full-text]
24. Comparison of 1.0-T extremity MR and 1.5-T conventional high-field-Strength MR in patients with rheumatoid arthritis.
    Radiology, 251(3): 829-37. [Abstract] [Full-text]

© 2004-2010 Rheumatoid Arthritis Research Today. All Rights Reserved.